Biohaven Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company that operates through a research-and-development model, generating value by advancing a diversified pipeline of small molecules and extracellular protein degraders. Following the $11.6 billion divestiture of its CGRP franchise to Pfizer, the company has pivoted to three primary segments: immunology (MoDE and TRAP degrader platforms), neuroscience (Kv7 ion channel modulation), and metabolic health (myostatin-activin inhibition). While the company currently reports no product revenue, it maintains a high-density pipeline targeting high-unmet needs in focal epilepsy, obesity, and autoimmune disorders like Graves' disease. Key direct competitors include Xenon Pharmaceuticals in the Kv7 space, Scholar Rock in myostatin inhibition, and Argenx in the immunology degrader market. Biohaven distinguishes itself through a "pipeline-in-a-product" strategy and a lean corporate structure, recently optimized in late 2025 to focus resources on late-stage assets like opakalim and taldefgrobep alfa. The company is led by its co-founder, Chairman, and CEO, Vlad Coric, M.D., a former Yale School of Medicine faculty member who orchestrated the landmark Pfizer acquisition. The executive leadership team includes Chief Financial Officer Matthew Buten, a veteran of healthcare investment banking, and Chief Medical Officer Irfan Qureshi, M.D., who oversees the clinical advancement of the company’s neuropsychiatric and rare disease programs. Biohaven’s pedigree is deeply rooted in its 2013 spin-off from Yale University, maintaining strong academic and strategic ties to the institution. The company is supported by a sophisticated investor base, including Janus Henderson Investors, T. Rowe Price, and BlackRock, and its board has historically featured industry luminaries such as former FDA Commissioner Scott Gottlieb.